

Complement: driver of inflammation and therapeutic target in diverse diseases

Monday 23 – Tuesday 24 February 2015

Organised by Professor Paul Morgan FMedSci and Professor Sir Peter Lachmann FMedSci FRS

THE
ROYAL
SOCIETY

DAY 1				DAY 2			
SESSION 1: Pathways to inflammation Chair: Keith Peters FMedSci FRS		SESSION 2: Complement dysregulation drives inflammation Chair: Peter Lachmann FMedSci FRS		SESSION 3: Strategies for inhibition Chair: Paul Morgan FMedSci		SESSION 4: Clinical trials of complement inhibition Chair: Mark Walport FMedSci FRS	
09:00	Welcome by Peter Knight FRS & Paul Morgan FMedSci						
09:05	Peter Lachmann FMedSci FRS The amplification loop drives inflammation	13:30	Santiago Rodriguez de Cordoba Complement genetics and susceptibility to inflammatory disease	09:00	Susan M. Lea Structure-guided drug design	13:30	Richard Smith Clinical trials with membrane targeting complement inhibitors
09:30	Discussion	14:00	Discussion	09:30	Discussion	14:00	Discussion
09:45	Hans-Wilhelm Schwaeble The lectin activation pathway of complement in health and disease	14:15	Matthew Pickering Complement dysregulation in C3 glomerulopathy	09:45	Tamar Grossmann Antisense therapies targeting complement in renal disease	14:15	Tim Goodship Patient stratification and therapy in aHUS
10:15	Discussion	14:45	Discussion	10:15	Discussion	14:45	Discussion
10:30	Coffee	15:00	Tea	10:30	Coffee	15:00	Tea
11:00	Paul Morgan FMedSci The membrane attack complex as an inflammatory trigger	15:30	Steven Sacks FMedSci Target discovery in the kidney transplant	11:00	Daniel Ricklin Aiming at the center: therapeutic intervention of complement-mediated diseases at the level of C3	15:30	Menno van Lookeren Campagne Targeting the alternative complement pathway in age-related macular degeneration
11:30	Discussion	16:00	Discussion	11:30	Discussion	16:00	Discussion
11:45	Marina Botto FMedSci Role of complement in autoimmunity – lessons from models and man	16:15	V. Michael Holers Targeting mechanisms at sites of complement activation for imaging and therapy	11:45	Markus Huber-Lang Targeting C5a and neutrophil activation	16:15	Summary of discussions and closing remarks Peter Lachmann FMedSci FRS
12:15	Discussion	16:45	Discussion	12:15	Discussion		
12:30	LUNCH	17:00	CLOSE	12:30	LUNCH	17:00	CLOSE

*Draft programme – correct as of **23/1/2015** – subject to change*